Adaptimmune Therapeutics company info

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics (NASDAQ:ADAP) focuses on the development of novel cancer immunotherapy products. Its main efforts are in spearheading the engineering of specific T-cell receptors (TCRs) for the treatment of cancer. Adaptimmune seeks to harness the power of the body's own immune system to target and destroy cancer cells by enhancing the natural ability of T-cells to fight the disease. With a pipeline of projects in various stages of development, the company aims to deliver innovative therapies for people with cancer, advancing treatments beyond current options. Their objective is to provide new, life-changing options for patients battling cancer, targeting a range of solid tumors and hematologic cancers.
Adaptimmune Therapeutics  company media

Company Snapshot

Is Adaptimmune Therapeutics a public or private company?

key

Ownership

Public

How many people does Adaptimmune Therapeutics employ?

people

Employees

491

What sector is Adaptimmune Therapeutics in?

pie chart

Sector

Health Care

Where is the head office for Adaptimmune Therapeutics ?

location pin

Head Office

Abingdon, United Kingdom

What year was Adaptimmune Therapeutics founded?

founded flag

Year Founded

2008

What does Adaptimmune Therapeutics specialise in?

/T-cell Therapy /Immuno-oncology Treatments /Cancer Therapies /Genome Editing /Clinical Trials /Pharmaceutical Research

What are the products and/or services of Adaptimmune Therapeutics ?

Overview of Adaptimmune Therapeutics offerings
SPEAR T-cell therapy platform, targeting cancer by engineering T-cells to recognize and attack tumors.
ADP-A2M4 for synovial sarcoma and MRCLS, a precision T-cell therapy.
ADP-A2M4CD8, an enhanced T-cell therapy targeting MAGE-A4 positive tumors with improved potency.
T-cell receptor (TCR) library, providing a diverse range of TCRs for rapid development of targeted therapies.
ADP-A2AFP, a T-cell therapy aimed at treating liver cancer by targeting AFP.
Next-generation T-cell therapies, ongoing research into dual-targeting TCRs for more complex tumor types.

Who is in the executive team of Adaptimmune Therapeutics ?

Adaptimmune Therapeutics leadership team
  • Photo of Mr. Adrian G.  Rawcliffe
    Mr. Adrian G. Rawcliffe
    CEO, Principal Accounting Officer & Director
  • Photo of Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
    Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
    Co-Founder & Chief Business & Strategy Officer
  • Photo of Mr. Gavin Hilary James Wood ACA, BA (Hons)
    Mr. Gavin Hilary James Wood ACA, BA (Hons)
    Chief Financial Officer
  • Photo of Mr. William C. A. Bertrand Jr., Esq., J.D.
    Mr. William C. A. Bertrand Jr., Esq., J.D.
    COO & Chief Compliance Officer
  • Photo of Dr. Elliot  Norry B.A., M.D.
    Dr. Elliot Norry B.A., M.D.
    Chief Medical Officer
  • Photo of Ms. Joanna  Brewer Ph.D.
    Ms. Joanna Brewer Ph.D.
    Chief Scientific Officer
  • Photo of Dr. Juli P. Miller Ph.D.
    Dr. Juli P. Miller Ph.D.
    VP of Corporate Affairs & Investor Relations
  • Photo of Ms. Kerry  Sharp
    Ms. Kerry Sharp
    Senior VP & General Council